Valuation: PYC Therapeutics Limited

Market Cap 1.67B 1.17B 1.02B 950M 872M 1.65B 112B 11.19B 4.39B 55.78B 4.41B 4.31B 187B P/E 2026 *
-23.8x
P/E 2027 * -18.5x
Enterprise Value 1.01B 707M 615M 572M 525M 992M 67.52B 6.75B 2.65B 33.62B 2.66B 2.6B 113B EV / Sales 2026 *
275x
EV / Sales 2027 * -
Free-Float
70.64%
Yield 2026 *
-
Yield 2027 * -
1 day+1.49%
1 week+2.41%
1 month+1.19%
3 months+38.78%
6 months+6.25%
Current year+2.72%
1 week 1.62
Extreme 1.62
1.76
1 month 1.49
Extreme 1.49
1.76
Current year 1.04
Extreme 1.045
1.76
1 year 0.85
Extreme 0.847
1.76
3 years 0.52
Extreme 0.52
2.1
5 years 0.5
Extreme 0.5
2.1
10 years 0.14
Extreme 0.14
2.1
Manager TitleAgeSince
Chief Executive Officer 42 2020-08-18
Director of Finance/CFO 47 2026-07-06
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 2018-11-29
Director/Board Member - 2025-09-21
Chairman 66 2025-11-17
Date Insider Type Main position Quantity % Market Cap.
12/23/25 Free

Chairman

2,000,000 0.3429%
11/26/25 Buy

Chief Executive Officer

133,350 0.0229%
2/27/25
Australia Land Pty Ltd.
BuyCompany 28,000,000 6.0008%
Change 5-day change 1-year change 3-year change Capi.($)
+1.49%+2.41%+40.50%+193.10% 1.17B
-1.40%+2.59%-1.71%+11.28% 48.53B
-2.41%-0.90%+411.96%+495.33% 39.87B
-1.16%+12.96%+28.81%+7.25% 38.68B
-1.88%-3.03%+5.69%+53.00% 35.13B
-1.74%+5.12%+14.44%+41.77% 29.79B
-0.21%-4.04%+36.40%+125.75% 16.11B
-2.85%-3.92% - - 16.08B
-0.64%+2.65%+3.40%+13.11% 13.61B
-1.19%-1.32%-1.73%-34.37% 12.62B
Average -1.20%+1.19%+59.75%+100.69% 25.16B
Weighted average by Cap. -1.58%+2.04%+79.59%+109.03%

Financials

2026 *2027 *
Net sales 3.67M 2.57M 2.24M 2.08M 1.91M 3.61M 246M 24.55M 9.63M 122M 9.67M 9.45M 410M -
Net income -57.43M -40.31M -35.05M -32.62M -29.95M -56.56M -3.85B -385M -151M -1.92B -151M -148M -6.42B -85.75M -60.19M -52.33M -48.7M -44.72M -84.44M -5.75B -574M -225M -2.86B -226M -221M -9.59B
Net Debt -664M -466M -405M -377M -346M -654M -44.51B -4.45B -1.75B -22.16B -1.75B -1.71B -74.31B -579M -406M -353M -329M -302M -570M -38.78B -3.87B -1.52B -19.31B -1.53B -1.49B -64.74B
Logo PYC Therapeutics Limited
PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002).
Employees
5
Date Price Change Volume
26-07-31 A$1.700 +1.49% 665,496
26-07-30 A$1.675 +3.08% 2,778,064
26-07-29 A$1.625 -.--% 1,699,137
26-07-28 A$1.625 -4.13% 697,004
26-07-27 A$1.695 +2.11% 1,457,478
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.700AUD
Average target price
3.752AUD
Spread / Average Target
+120.71%

Quarterly revenue - Rate of surprise